# US 12,180,307 B2 · Interleukin-13 binding cyclic oligopeptides and methods of use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,180,307 B2 - Document ID: US12180307B2 - Status: Granted - Kind: B2 - Application number: 18/334,309 - Filed: 2023-06-13 - Published: 2023-12-14 - Granted: 2024-12-31 - Earliest claimed: 2022-06-13 - Assignees: B.A.I. Laboratories, LLC - Applicants: B.A.I. Laboratories, LLC - Inventors: Xuefei Bai; Sheng Lin; Le Li - Web page: https://patentgrep.com/patent/US12180307B2 ## CPC - C07K 7/64: Cyclic peptides containing only normal peptide links - A61P 17/00: Drugs for dermatological disorders - A61P 37/00: Drugs for immunological or allergic disorders - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present disclosure relates to cyclic oligopeptides that bind to interleukin-13 (IL-13) which are useful therapeutically in methods of treating or preventing IL-13-associated skin disorders or conditions. The present disclosure also provides methods to treat or prevent IL-13-associated skin disorders or conditions with the IL-13-binding cyclic oligopeptides. The present disclosure further provides methods to produce the IL-13-binding cyclic oligopeptides. ## Claims ### Claim 1 A cyclic oligopeptide, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11 and or a pharmaceutically acceptable salt of any of the foregoing. ### Claim 2 (depends on 1) The cyclic oligopeptide of claim 1, wherein the cyclic oligopeptide has is selected from the group consisting of any one of Compounds 1-11 and ### Claim 3 A pharmaceutical composition comprising a cyclic oligopeptide and a pharmaceutically acceptable carrier, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11 or a pharmaceutically acceptable salt of any of the foregoing. ### Claim 4 (depends on 3) The pharmaceutical composition according to claim 3, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11 ### Claim 5 (depends on 3) The pharmaceutical composition according to claim 3, wherein the composition is formulated for topical administration. ### Claim 6 (depends on 4) The pharmaceutical composition according to claim 4, wherein the composition is formulated for topical administration. ### Claim 7 A method of treating atopic dermatitis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a cyclic oligopeptide or a pharmaceutical composition comprising the cyclic oligopeptide and a pharmaceutically acceptable carrier, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11 or a pharmaceutically acceptable salt of any of the foregoing. ### Claim 8 (depends on 7) The method of claim 7, wherein the cyclic oligopeptide is selected from the group consisting of any one of Compounds 1-11 ### Claim 9 (depends on 7) The method according to claim 7, wherein the cyclic oligopeptide or pharmaceutical composition is administered topically. ### Claim 10 (depends on 8) The method according to claim 8, wherein the cyclic oligopeptide or pharmaceutical composition is administered topically.